Currently Enrolling Trials
Veregen (kunecatechins) 15% is a botanical drug product for topical use. It is comprised of kunecatechins, which is a partially purified fraction of the water extract of green tea leaves, and is a mixture of catechins and other green tea components. Catechins are bioflavonoids, polyphenols and powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.
Veregen is specifically indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Veregen is supplied as an ointment for topical administration. The recommended initial dose of the drug is a 0.5 cm strand applied in a thin layer over all external and perianal warts, three times a day. Treatment should not exceed 16 weeks.
FDA approval of Veregen was based on the pooled results of two randomized, double-blind, vehicle-controlled phase III clinical trials. These trials enrolled a combined 1,000 immunocompetent subjects who received the ointment three times daily for up to 16 weeks or until complete clearance of all warts. The primary endpoint was the response rate defined as the proportion of patients with complete clinical (visual) clearance of all external genital and perianal warts (baseline and new) by week 16. Of the subjects treated with Veregen, 53.6% reached complete clearance versus 35.3% on placebo. The median time to complete wart clearance was 16 weeks and 10 weeks, respectively, in the two trials.
Ongoing Study Commitments
- Medigene has agreed to a phase 4 study comparing the
pharmacokinetics of catechin following topical application of
Veregen Ointment, 15%, with that obtained after oral administration
of green tea solution. The two-arm study will be designed to enroll
into one arm 20 evaluable patients (completer) with external
genital and perianal warts who will be treated 3 times daily for 7
days with Veregen Ointment, 15%, and into the second arm 20
evaluable healthy volunteers, who are to drink a green tea solution
3 times daily for 7 days. Blood samples for the analysis of
catechin levels will be obtained prior to and at several sampling
time points (over 12 hours) after oral intake of a green teal
solution or topical application of Veregen Ointment, 15%,
respectively, at Days 1 and 7. The study will be carried out with
material from the final commercial source for API to be established
in Japan and fulfilling the FDA-defined specifications for the
botanical drug substance and drug product.
Protocol Submission: July 2007
Study Start: January 2008
Final Report Submission: January 2009
Adverse events associated with the use of Veregen may include, but are not limited to, the following:
- Rash vesicular
Mechanism of Action
Veregen is a botanical drug product for topical use. The drug substance in Veregen is Kunecatechins, which is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis O Kuntze, and is a mixture of catechins and other green tea components. While the exact mechanism of action of catechins is unknown, they are powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.
Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jun 15;11(12):4627-33.
Lee WJ, Shim JY, Zhu BT Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular pharmacology 2005 Oct;68(4):1018-30. Epub 2005 Jul 21.
Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Aug 15;9(9):3312-9.